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Introduction. Sensitive and specific imaging of pancreas cancer are necessary for accurate diagnosis, staging, and treatment. The
vast majority of pancreas cancers express the carbohydrate tumor antigen CA19-9. The goal of this study was to determine the
potential to target CA19-9 with a radiolabeled anti-CA19-9 antibody for imaging pancreas cancer.Methods. CA19-9 was quantified
using flow cytometry on human pancreas cancer cell lines. An intact murine anti-CA19-9 monoclonal antibody was labeled
with a positron emitting radionuclide (Iodine-124) and injected into mice harboring antigen positive and negative xenografts.
MicroPET/CT were performed at successive time intervals (72 hours, 96 hours, 120 hours) after injection. Radioactivity was
measured in blood and tumor to provide objective confirmation of the images. Results. Antigen expression by flow cytometry
revealed approximately 1.3 × 106 CA19-9 antigens for the positive cell line and no expression in the negative cell line. Pancreas
xenograft imaging with Iodine-124-labeled anti-CA19-9 mAb demonstrated an average tumor to blood ratio of 5 and positive to
negative tumor ratio of 20. Conclusion. We show in vivo targeting of our antigen positive xenograft with a radiolabeled anti-CA19-9
antibody. These data demonstrate the potential to achieve anti-CA19-9 antibody based positron emission tomography of pancreas
cancer.
1. Introduction
Pancreatic cancer is one of the most lethal cancers where
incidence approximates mortality [1]. Symptoms of pancre-
atic cancer are vague and usually occur late in the disease
process. As a result, 80% of all pancreas cancer patients have
metastatic disease at diagnosis [2] leading to poor patient
outcomes with overall actual 5-year survival of approximate-
ly 6% [3]. Even for the 10–20% who undergo surgical resec-
tion, overall 5-year survival is only 25% due to the presence
of small foci of metastatic disease in the lymph nodes or
liver that are unrecognized by our current imaging (CT/
MRI/FDG-PET) [4–6]. These data indicate that patients are
routinely understaged and underscore the need for improved
imaging techniques to accurately detect the true burden of
disease.
Molecular imaging shows great promise to provide sen-
sitive and tumor-specific imaging. The most commonly used
molecular imaging modality is positron emission tomogra-
phy (PET). It has been estimated that PET technology has
the potential to provide highly sensitive imaging based on
its ability to detect nanomolar to subnanomolar concentra-
tions of radiolabeled imaging agents and provide 1-2mm
spatial resolution [7]. Most often in the clinical setting, PET
scanning technology uses 2-deoxy-2-[18F]fluoro-D-glucose
(FDG) as the imaging agent, taking advantage of a tumor
cell’s metabolic dependence on glycolysis (the Warburg ef-
fect), which results in increased glucose uptake relative to
nonmalignant cells. Although FDG-PET has shown great
potential to image many cancers, it has limited utility in pan-
creas cancer secondary to a lack of sensitivity and spec-
ificity [8–12]. With the introduction of radiolabeled an-
tibodies and antibody fragments as PET imaging agents,
immunoPET exploits the inherent sensitivity of PET to
provide tumor-specific imaging. Specifically, monoclonal
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antibodies (mAbs), which offer high specificity for epitopes
known to be differentially expressed on cancer cells, can
be labeled with a positron emitting radionuclide to provide
antigen-specific PET images.
With respect to pancreas cancer, CA19-9 is the most
highly expressed tumor antigen, present on cellular mem-
brane proteins in more than 90% of patients [13–17]. This
tumor antigen is minimally expressed in normal pancreas
epithelial [18, 19]. The molecular mechanism responsible for
the increased expression of CA19-9 in pancreas cancer is sec-
ondary to aberrant glycosylation of proteins upon malignant
transformation of epithelial cells [20–22]. The relatively high
expression of CA19-9 on membrane proteins of the pancreas
cancer cells represents an attractive target for the develop-
ment of pancreas cancer-specific targeting agents. Moreover,
since the CA19-9 epitope can be present in multiple copies
on a single membrane protein, the potential of being able to
target more than one epitope per membrane protein exists,
giving CA19-9 a theoretical advantage over other protein
tumor antigens like CEA. Thus, we decided to investigate the
usefulness of CA19-9 as a tumor target for pancreatic cancer
immunoPET.
Our first objective was to develop and characterize a
preclinical xenograft model which recapitulates the human
condition of pancreatic cancer with respect to CA19-9 ex-
pression. To this end, we evaluated and quantified CA19-9
expression on our human pancreatic cancer cells by flow
cytometry and performed immunohistochemical staining of
our xenografts to compare to human cases of pancreas can-
cer. Finally, we tested our ability to obtain antigen-specific
PET imaging of our pancreas cancer xenografts utilizing a
radiolabeled anti-CA19-9 monoclonal antibody.
2. Methods
2.1. Production of Anti-CA19-9 Antibody. Hybridoma cells
(1116-NS-19-9) that secrete the intact mouse monoclonal
anti-CA19-9 antibody were purchased from the American
Type Culture Collection (ATCC, Manassas, VA). These cells
were maintained as recommended by the ATCC and supple-
mented with 1% penicillin/streptomycin (Invitrogen, Carls-
bad, CA). Cells were grown and expanded into triple flasks
(Nunclon, Rochester, NY). Supernatants from terminal cul-
tures were harvested from triple flasks, centrifuged to remove
cell debris, and sterile filtered. Proteins from the supernatant
were purified using affinity chromatography with a 1mL
Protein G column (Applied Biosystems, Carlsbad, CA) on
an AKTA Purifier (GE Healthcare, Piscataway, NJ). Bound
protein was eluted at 30% 0.2M citric acid buffer, pH 2.1
and phosphate buffered saline (PBS). Eluted proteins were
immediately brought back to neutral pH with 1M Tris-
buffer, titrated to pH 8.2 with 6M NaOH. All fractions
were analyzed by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE). Fractions containing the pro-
tein of interest were pooled, and dialyzed against PBS using
a Slide-A-Lyzer Dialysis Cassette, molecular weight cutoff
30,000 daltons (Thermo Fisher Scientific, Rockford, IL). Pure
protein was then concentrated by Vivaspin 20, molecular
weight cutoff 30,000 daltons (Thermo Fisher Scientific), and
the final concentration was determined by A280 nm using an
extinction coefficient of ε = 1.4.
2.2. Characterization of Purified Antibody. Purified antibody
was analyzed by SDS-PAGE on pre-cast 4–20% polyacry-
lamide Ready Gels (Bio-Rad Laboratories, Hercules, CA)
under reducing (1mmol/LDTT) and nonreducing condi-
tions. The proteins were detected by staining withMicrowave
Blue (Protiga Inc., Frederick, MD). Western blot using
alkaline phosphatase (AP) conjugated goat antimouse IgG,
Fc specific, (Jackson ImmunoResearch Labs,West Grove, PA)
antibody (1 : 5000) was used to confirm the results seen on
SDS-PAGE.Western blots were developed with 33 μL of stan-
dard stock solution of BCIP (5-bromo-4-chloro-3′-Indolyl
phosphate p-toluidine salt, Bio-Rad Laboratories) and 66 μL
of standard stock solution of NBT (nitro-blue tetrazolium
chloride, Bio-Rad Laboratories) in 10mL of AP buffer. Sam-
ples were also subjected to size exclusion chromatography
(SEC) on a Superdex 200 HR 10/30 column (GE Healthcare,
Piscataway, NJ) run isocratically in PBS. A 100 μL volume
containing 50 μg of pure protein was loaded onto the column
and eluted with PBS at a flow rate of 0.5ml/min. Elution
time was compared to bovine serum albumin (66 kDa) and
β-amylase (200 kDa) standards (Sigma). The anti-CA19-9
antibody dissociation constant (i.e., binding affinity) was
determined by cell-based ELISA. Cells were harvested, and
approximately 5 × 104 were transferred to each well of a 96-
well round bottom plate (Costar, Corning, NY) and incubat-
ed overnight. The following day each well was washed with
150 μL of PBS and incubated with increasing concentrations
of antibody (0.01–100 nM). After one hour incubation, the
wells were washed and incubated for another hour with
a fixed concentration (1 : 1000) of AP-conjugated goat anti
mouse IgG, Fc specific (Jackson ImmunoResearch) antibody.
The cells were washed again and developed with phosphatase
substrate tablets (Sigma) dissolved in diethanolamine buffer,
pH 9.8. All assays were carried out in triplicate.
2.3. Antigen Expression and Quantitation. The expression of
CA19-9 was determined for each cell line by flow cytometry.
For each cell line, 1 × 106 cells were harvested from culture
and resuspended in 250 μL of Phosphate Buffered Saline/1%
Fetal Bovine Serum (PBS/1%FBS). Purified intact mouse
anti-CA19-9 antibody was added in excess (4 μg) and incu-
bated for 1 hour. The samples were centrifuged at 1000 g for
10 minutes, and the supernatant was discarded. Following a
wash step, the samples were each resuspended in 250 μL of
PBS/1% FBS. Four micrograms of the secondary antibody,
phycoerythrin (PE) conjugated, goat antimouse IgG (Fc
specific), antibody (Jackson ImmunoResearch Labs), were
then added to each sample and incubated for 1 hour. After
a final wash step, cells were resuspended in PBS/1% FBS
and the fluorescence associated with the cells was measured.
Negative controls included samples with cells only and sam-
ples with only secondary antibody. Quantitation of antigen
expression for each cell line was performed using the Dako
Qifikit according to the manufacturer’s instructions (DAKO,
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Carpinteria, CA) using fluorescein (FITC) conjugated, goat
anti mouse IgG (Fc specific) antibody. Antigen expression is
referred to as antigen density and recorded as antigens per
cell. All assays were performed in triplicate.
2.4. Immunohistochemistry. Surgically resected human pan-
creas cancer specimens were provided by the Department
of Pathology at the University of California, Los Angeles
(UCLA) Medical Center under an approved Institutional
Review Board (IRB) protocol. These specimens were evalu-
ated by IHC for expression of CA19-9 using the monoclonal
mouse anti-CA19-9 antibody. Each paraffin embedded speci-
menwas deparaffinized and incubated with the primary anti-
CA19-9 antibody (1 : 50) for 1 hour. Specimens were washed
with PBS/1% Tween and then incubated with the secondary
horseradish peroxidase (HRP) conjugated goat anti mouse
IgG (Fc specific) antibody (1 : 400) (DAKO). Negative con-
trol slides were incubated with the secondary antibody only.
2.5. Cell Lines. The human pancreatic cancer cell lines,
BxPC3 and MiaPaca-2, were purchased from the ATCC and
maintained in RPMI-1640 medium and DMEM, respec-
tively. All media were supplemented with 100 units of pen-
icillin and 100 μg of streptomycin (Invitrogen) and 10%FBS.
DMEM for MiaPaca-2 was also supplemented with 2.5%
horse serum (Invitrogen).
2.6. Radioiodination. Radioiodination with the positron
emitting isotope 124I was performed by the Iodo-Genmethod
as described [23]. The labeling reaction (0.1ml) contained
0.1–0.2mg purified protein and 0.5–1mCi Na 124I (IBA
Molecular North America, Dulles, VA). Labeling efficiency
was measured by instant TLC using the Tec-Control kit
(Biodex Medical Systems, Shirley, NY). Immunoreactivity
was determined by incubating the radioiodinated antibody
(≈100,000 cpm) with BxPC3 cells in PBS/1% FBS such that
there was an excess of antigen present. The radioiodinated
antibody was allowed to incubate for 1 hour before the
samples were washed with PBS/1%FBS. Any radioactivity
not bound to cells was collected in the supernatant and
measured in a gamma counter (Wizard 3′′ 1480 Automatic
Gamma Counter, Perkin-Elmer, Covina, CA). This fraction
was divided by the total known amount of radioactivity
added to the cells to yield the portion of unbound antibody.
The amount of unbound antibody was subtracted from 1 to
yield the portion of bound antibody (Immunoreactivity).
2.7. Xenograft Imaging and Biodistribution Studies. All ani-
mal handling was done under a protocol approved by the
Chancellor’s Animal Research Committee of the University
of California in Los Angeles (UCLA). Mouse xenografts
were created by injecting subcutaneously 1× 106 of antigen-
negative (MiaPaca-2) and antigen-positive (BxPC3) cells into
the right and left shoulders of 8-week-old, female nude
mice, respectively. Xenografts were grown for approximately
3 weeks. Stomach uptake was blocked by performing gastric
lavage with 1.5mg of potassium perchlorate in 0.2mL of
PBS 30 minutes prior to injection. Thyroid uptake was not
blocked. Each mouse was injected with an equal volume of
the radiolabeled antibody from the radioiodination reaction
batch. This ensured that each mouse received a similar
amount of radiolabeled antibody. Mice were injected with
approximately 35 μg of 124I-anti-CA19.9 antibody (specific
activity of 3.1 ± 1.7 μCi/μg) in PBS via the tail vein. At
72, 96, and 120 hours postinjection, the mice were anes-
thetized using 2% isoflurane, placed on the microPET bed,
and imaged with a Focus microPET scanner (Concorde
Microsystems Inc., Knoxville, TN). Acquisition time was 10
minutes. All images were reconstructed using an FBP algo-
rithm and displayed by the AMIDE software package [24,
25]. After the final microPET imaging time point, selected
animals were also imaged by microcomputed tomography
(microCT) for anatomic reference and subsequent coregis-
tration with microPET images. Following the last scanning
time point, animals were euthanized; tumors, blood, kidneys,
liver, spleen, stomach, pancreas, lungs, and carcass were
harvested and weighed. Radioactive uptake of organs was
counted in a gamma counter (Wizard 3′′ 1480 Automatic
Gamma Counter, Perkin-Elmer, Covina, CA) for biodistri-
bution analysis. After decay correction, radioactive uptake in
organs was converted to percentage of injected dose per gram
tissue (%ID/g).
2.8. Serum CA19-9 Measurement. Serum CA19-9 level was
performed for mice bearing antigen-positive xenografts
alone and antigen-negative xenografts alone. Four nude mice
were injected s.c. with 1 × 106 cells. Two mice harbored the
MiaPaca-2 xenograft and the other two harbored the BxPC3
xenograft. Xenografts were permitted to grow for 3 weeks.
After sacrificing the animals, heart puncture was performed
to obtain blood samples. Using the Cancer Antigen CA19-9
ELISA test kit (Panomics, Fremont, CA) and following the
manufacturer’s instructions, blood samples were tested for
CA19-9 levels based on standards provided by the kit. For
each animal, 3 blood samples were obtained and analyzed for
CA19-9 levels, totaling 6 samples for animals with CA19-9
positive tumors and 6 samples for CA19-9 negative tumors.
3. Results
3.1. Production and Biochemical Characterization of the Anti-
CA19-9 Antibody. The level of antibody production of hy-
bridoma cells following expansion in triple flasks was ap-
proximately 20 μg/ml. SDS-PAGE under reducing and non-
reducing conditions was used to confirm the purity of the
anti-CA19-9 antibody after purification. The migration of
the anti-CA19-9 antibody was consistent with the known
molecular weight of intact antibodies (approx. 150 kDa). Re-
ducing conditions yields the two expected fragments corre-
sponding to the heavy and light chains of the antibody. West-
ern blot probing for the murine Fc region confirmed protein
identity (data not shown). Size exclusion chromatography
shows that the intact anti-CA-19-9 monoclonal antibody
elutes between the BSA (66 kDa) and β-amylase (200 kDa)
standards at 25.7 minutes consistent with published results
4 International Journal of Molecular Imaging
0.1 1 10 100
Binding affinity of the intact anti-CA19-9 antibody







































100 101 102 103 104
(b)
Figure 1: In vitro functional characterization of the anti-CA19-9 intact murine antibody. (a) Equilibrium binding affinity constant as
determined by cell-based ELISA of the anti-CA19-9 antibody. (b) Flow cytometry showing binding specificity of the anti-CA19-9 antibody
to each human cancer cell line. Red line represents cells only. Blue line represents cells incubated with only PE-conjugated goat antimouse
antibody. Green line represents cells incubated with intact mouse anti-CA19-9 antibody and PE-conjugated goat antimouse antibody.
for IgG1 subtype antibodies [26]. Cell-based ELISA esti-
mated the approximate equilibrium binding affinity constant
(KD) of the anti-CA19-9 antibody to be in the range of 12–
15 nM (Figure 1(a)).
3.2. Antigen Expression and Quantitation. Flow cytometry
confirmed high expression of CA19-9 on the human pan-
creatic cancer cell line, BxPC3, and very low expression
on MiaPaca-2 (Figure 1(b)). Quantitative flow cytometry
showed that the BxPC3 cell line exhibited approximately
1.3 × 106 CA19-9 epitopes per cell, while the MiaPaca-2
showed less than 400 epitopes per cell.
3.3. Immunohistochemistry. Expression of CA19-9 on hu-
man pancreas cancer specimens from surgically resected tu-
mors was evaluated using IHC. Of the fourteen human pan-
creatic adenocarcinoma specimens evaluated, 12 were posi-
tive for CA19-9 expression yielding an 86% positivity of the
small sample of human tumors that we evaluated (Figure 2).
Normal liver and pancreas specimens showed little or no
staining confirming low to absent expression in these normal
tissues. Anti-CA19-9 IHC staining was noted to be of similar
intensity between human pancreas cancer specimens and
mouse xenografts specimens.
3.4. Radioiodination, Xenograft Imaging, and Biodistribution
Studies. Radioiodination with 124I was conducted with a
labeling efficiency of 49%. Immunoreactivity of the radi-
olabeled fraction was 60%. For animal studies, microPET
was employed to evaluate in vivo antigen-specific tumor
targeting ability of the anti-CA19-9 antibody. Three nude
mice, each harboring a CA19-9 positive tumor (BxPC3) and
CA19-9 negative tumor (MiaPaca-2) were injected via the
tail vein with approximately 35 μg of 124I labeled anti-CA19-
9 antibody. Each injection was approximately 120 μCi of
radioactivity. Average tumor weight for all positive tumors
(n = 3) was approximately 81mg (range, 13–221mg).Whole
body microPET scans were obtained at 72, 96, and 120 hours
after injection. MicroCT was obtained at 120 hours only.
Figure 3 illustrates a representative image of one animal at
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Figure 2: Immunohistochemistry with the anti-CA19-9 antibody (magnification 40x). (a) Human pancreas cancer specimen. (b) BxPC3
xenograft. (c) Normal human pancreas section. (d) Normal human liver section.
each of the different time points. Images shown indicate
specific uptake of the radiolabeled anti-CA19-9 antibody on
the left shoulder of the mouse where positive xenografts were
grown. There is a decreasing amount of background activity
visualized by microPET at the later time points. In addition,
Figure 3 shows the average percent of injected dose per gram
of tissue (%ID/g) for blood, positive tumor, and negative
tumor to provide objective confirmation of the radioactivity
giving rise to the microPET images. Average blood %ID/g
was 0.16 (±0.02) with an average negative tumor %ID/g of
0.04. The %ID/g for each positive tumor was 0.45, 0.54, and
1.43 with an average of 0.80. The average tumor to blood
(%ID/g) ratio was 5.0 (n = 3), and average positive tumor
to negative tumor (%ID/g) ratio was 20.0 (n = 1). We
found the difference between the average tumor and average
blood in the 3 animals to trend toward statistical significance
(P = 0.056).
3.5. Serum CA19-9 Measurement. Serum CA19-9 measure-
ment in mice harboring the antigen-positive xenograft
(BxPC3) or antigen-negative xenograft (MiaPaca-2) with
tumors similar in size to those mice used for imaging
experiments (7–10mm). BxPC3 xenograft mice had an aver-
age CA19-9 level of 45 units/mL (range of 25–65 units/ml),
while MiaPaca-2 xenograft mice demonstrated less than
5 units/mL of CA19-9 in the blood.
4. Discussion
Pancreatic adenocarcinoma is one of the most lethal cancers
with a poor overall survival. Most patients have metastatic
disease at the time of presentation. For patients who present
without evidence of metastatic disease, survival outcomes
are only marginally better secondary to the presence of mi-
crometastatic disease, which is not detected by our current
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Figure 3: In vivo MicroPET images of BxPC3 xenografts. (a) Image at 72 hours. (b) Image at 96 hours. (c) Coregistered microPET/microCT
Image at 120 hours. White arrows point to the BxPC3 tumor on the left shoulder of the mouse. Tumor to blood and positive tumor to
negative tumor ratios of %ID/g determined from biodistribution data acquired at the 120 hour time point are indicated below the images.
imagingmodalities (CT/MRI/FDG-PET). Cure is only achieved
in the small fraction of patients that undergo surgical re-
section and have no metastatic or micrometastatic disease.
Thus, the vast majority of patients with pancreas cancer un-
dergo chemotherapy with inherent systemic toxicity and lim-
ited efficacy. Most recent randomized chemotherapy trials in
stage IV pancreas cancer report survival benefit in the range
of 1–4 months [27, 28]. These data indicate the need for
development of novel agents to specifically target pancreas
cancer for both imaging and therapy.
Since the advent of hybridoma technology approximately
30 years ago, the use of antibodies to treat as well as diagnose
a variety of diseases has grown tremendously. Currently,
antibody pharmaceuticals represent one of the fastest grow-
ing classes of therapeutics in the biotechnology industry
[29]. Traditionally, antibodies have been used for ex vivo
immunohistochemistry of tissues for cancer diagnosis. The
murine monoclonal antibody N19-9, which recognizes the
tumor antigen CA19-9, has been used over the last 25 years
for testing patients’ sera and histologic sections of pancreatic
adenocarcinomas for the presence of CA19-9 in the diagnosis
of pancreas cancer [13, 30]. Based on its utility in evaluating
the presence of CA19-9 on ex vivo tissues specimens, we
sought to investigate the potential to target CA19-9 in vivo
for PET imaging of pancreas cancer with a radiolabeled anti-
CA19-9 antibody.
CA19-9, also referred to as sialyl Lewis a, is known to be
abundantly expressed in >90% of pancreatic cancer cases.
The increased expression of CA19-9 is related to aberrant
glycosylation of membrane proteins upon malignant trans-
formation of normal pancreatic ductal epithelial cells [20–
22]. This aberrant glycosylation has been reported to be
secondary to downregulation of certain glycosyltransferases
resulting in truncated glycosylation products such CA19-9
[20, 21]. In contrast, CA19-9 is expressed minimally on nor-
mal pancreaticobiliary epithelial cells. Moreover, its limited
expression is restricted to the apical brush border which is a
relatively inaccessible location to targeting agents secondary
to tight junctions of mature and polarized ductal epithelia
[31]. Upon malignant transformation, epithelial cells lose
polarity and glycosylated membrane proteins are no longer
exclusively restricted to only a portion of the cell membrane
[31]. Therefore, not only does malignant transformation of
a pancreas epithelial cell yield aberrant glycosylation and
increased production of CA19-9, but also leads to increased
accessibility of this antigen.
As a carbohydrate tumor antigen, CA19-9 has a couple of
theoretical advantages over conventional protein epitopes in
relation to targeting. The first is location of the carbohydrate
antigen and the second is the abundance of the epitope.
Because CA19-9 is part of a cell’s glycan, sugar moieties like
CA19-9 are presented at the outermost extent of the cell
membrane such that targeting agents such as antibodies can
easily access it. Secondly, the epitope can exist in numerous
copies per protein resulting in a significant increased presen-
tation of antigen compared to other protein antigens such as
CEA. For these reasons, CA19-9 is an attractive antigen target
for the development of antibody-based imaging and therapy
for pancreas cancer. Our study represents the initial experi-
ments in demonstrating the potential to target CA19-9 with
a radiolabeled intact antibody for immunoPET applications.
First, we sought to characterize and establish a pancreas
cancer model with respect to CA19-9 expression. We initially
tested our cell lines for expression of CA19-9 qualitatively
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and determined a high level of expression on the BxPC3
cancer cell line and no expression on the MiaPaca-2 cell line.
We then quantified CA19-9 expression on these cell lines and
found 1.3 × 106 CA19-9 antigens per BxPC3 cell. For com-
parison, we tested the well-known high expressing human
colon cancer cell line LS174T for carcinoembryonic antigen
(CEA) and found approximately 130,000 CEA antigens per
cell (data not shown). Based on these results, CA19-9 antigen
density per cell is roughly 10x as abundant as CEA indicating
a potential advantage as an antigen for targeting. To further
characterize our model, we performed IHC on human pan-
creas cancer specimens as well as our BxPC3 xenograft and
found similar staining intensity for CA19-9. Additionally, in
order to confirm previous reports that over 90% of pancreas
cancers actually express CA19-9, we evaluated 14 surgically
resected human pancreas cancer specimens for the presence
of CA19-9 by IHC. Of the 14 specimens, 12 showed mod-
erate to strong staining for CA19-9, consistent with results
described in the literature [13, 14]. Finally, to further validate
our pancreas cancer xenograft model, we tested the blood
of mice carrying the antigen-positive xenograft as well as
the blood of mice with the antigen-negative xenograft. We
determined that the average blood CA19-9 level for mice
with the antigen-positive xenograft was 45 units/mL and
less than 5 units/mL for mice with antigen-negative xeno-
grafts. This demonstrates shedding of CA19-9 into the blood
as observed in patients with pancreas cancer. Having charac-
terized our preclinical xenograft model and shown that it is
similar to the human cases of pancreas cancer with respect to
CA19-9 expression, we hypothesized that we could use radio-
labeled anti-CA19-9 monoclonal mouse antibody to achieve
antigen-specific targeting of a CA19-9 positive mouse xeno-
graft for PET imaging.
After successfully purifying and radiolabeling the N19-9
antibody with the positron emitting isotope (Iodine-124), it
was injected into the tail vein of mice harboring a CA19-
9-positive and -negative xenograft such that each mouse
served as its own control. Given the anticipated long serum
persistence of the intact murine antibody in a mouse, we
empirically choose our initial microPET imaging to be per-
formed at 72 hours. Even though the background signal was
still significant at 72 hours, we were able to discern that the
radiolabeled anti-CA19-9 antibody was preferentially target-
ing the tumor. Based on these initial microPET images, we
decided to image at 96 and again at 120 hrs after injection.
Our microPET images at 120 hours were so convincing of
antigen-specific tumor targeting with low background ac-
tivity that we choose to perform the microCT scan and
terminate the experiment. The animals were euthanized im-
mediately after the microCT scan and the tumors and blood
were harvested and the radioactivity was counted in order to
determine the percentage of injected dose per gram of tissue
to provide objective evidence that our radiolabeled anti-
CA19-9 antibody preferentially targeted the CA19-9-positive
tumor. The tumor to blood ratio of 5.0 represents 5 times
more radioactivity at the tumor site compared to the blood,
which provided an adequate amount of signal contrast be-
tween the tumor tissues and background (i.e., blood) to
generate our anti-CA19-9 microPET images. Additionally,
the positive tumor to negative tumor ratio was 20, signifying
specific targeting of the anti-CA19-9 antibody to the antigen-
positive tumor instead of nonspecific tumor accumulation
through other mechanisms such as the phenomenon known
as enhanced permeability and retention [32]. These results
provide promising evidence of the utility of CA19-9 as a
target for imaging pancreatic cancer.
Although we were able to achieve antigen-specific mi-
croPET imaging of mouse xenografts with the anti-CA19-9
antibody, there are some limitations and hurdles that must
be overcome before translation into clinical practice. First,
the large size of the intact antibody is not ideal for imaging
purposes [33]. The long serum half-lives of intact antibodies
(10–20 days) cause an extended serum persistence resulting
in high background signal and thus reduced contrast for
imaging [34]. Although we were able to achieve significant
contrast using an intact antibody after 5 days in the mouse,
practical imaging applications for humans would most likely
need to conform to a time frame of 24 hours or less after
injection of an imaging agent. Alternatively, antibodies with
shorter half-lives ranging from 2 hours to 10 days can be
engineered to fit the purpose of imaging. In particular,
Williams et al. found that the ideal same-day imaging agent
would be the diabody (scFv dimer; 55 kDa) when compared
to the intact antibody, F(ab′)2 fragment (110 kDa), and
minibody (80 kDa) [35]. Moreover, the intact anti-CA19-9
antibody is a murine monoclonal antibody and would in-
itiate a human anti mouse antibody (HAMA) response if
administered to humans, preventing subsequent administra-
tions of the antibody. In order to enable translation into
humans, a chimeric antibody at the very least, with human
constant regions, would need to be created. In light of these
known limitations, we are currently working to create an ar-
mamentarium of engineered chimeric anti-CA19-9 antibody
fragments with different sizes and pharmacokinetics so that
we may select the most suitable fragment for imaging and/or
therapy.
In summary, novel molecular imaging techniques such as
ImmunoPET imaging have the potential to provide a more
clear assessment of the true burden of disease for pancre-
atic cancer patients. Furthermore, noninvasive imaging as a
bridge to targeted therapy also has obvious advantages over
our current delivery and evaluation of nontargeted chem-
otherapeutics. CA19-9 is expressed on almost all pancreas
cancers and thus is a potential target for antibody-based mo-
lecular imaging or therapy of pancreas cancers. In this study,
we characterized a pancreas cancer xenograft model, which
recapitulates human pancreas cancer with respect to the an-
tigen CA19-9 expression. Utilizing this model we demon-
strated the ability to target CA19-9 with a radiolabeled anti-
CA19-9 antibody and produced antigen-specific microPET
images. Future studies investigating the utility of engi-
neered chimeric antibody fragments are currently underway.
Through these studies, we hope to develop anti-CA19-9-
based tumor targeting agents that can be clinically translated
for not only novel imaging techniques but also as targeted
therapeutics in the fight against pancreas cancer.
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